Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Adam Wilks
AddedMar 31, 2024
UpdatedMay 31, 2026
Adam Wilks

Adam Wilks

CEO, Captor Capital

LinkedIn

Adam Wilks's Career

Captor Capital
Captor Capital

Toronto, Ontario, CA

CEO· C-Suite · Management
Tyson 2.0
Tyson 2.0

Chicago, IL, US

CEO· C-Suite · Management
Old Pal
Old Pal

California, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Adam Wilks's Career

Captor Capital
Captor Capital
Investment FirmInvestment Firm1052003Toronto, Ontario, CA
CEO· C-Suite · Management

Leadership at Captor Capital

Alex SpiroAlex SpiroBoard Member
John ZorbasJohn ZorbasBoard Member
BRADY COBBBRADY COBBBoard Member
Bryan ReyhaniBryan ReyhaniBoard Member
Kyle ApplebyKyle ApplebyBoard Member

Similar to Captor Capital

Captra CapitalCaptra CapitalDallas, TX, USCaptra CapitalDallas, TX, US

Captra Capital: An innovative infrastructure investment firm, creating value and growth through essential asset investments.

Investment Firm30
Cap-Meridian VenturesCap-Meridian VenturesNew York City, NY, USest. 2011Cap-Meridian VenturesNew York City, NY, US · est. 2011

NYC-based Cap-Meridian Ventures is a global private investment firm funding diverse assets.

Investment Firm50
CapitoriaCapitoriaLondon, Greater London, GBest. 2017CapitoriaLondon, Greater London, GB · est. 2017

Founded in 2017, Capitoria is a dynamic venture capital firm.

Investment Firm4
Captive CapitalCaptive CapitalKing of Prussia, PA, USest. 1999Captive CapitalKing of Prussia, PA, US · est. 1999

Captive Capital Corp: A US-based financial services provider offering intermediate to long-term general and industrial credit.

Investment Firm · $5M20
Tyson 2.0
Tyson 2.0
Series A$26.6M302021Chicago, IL, US
CEO· C-Suite · Management

Leadership at Tyson 2.0

Chad BronsteinChad BronsteinBoard Member
Aristotle LoumisAristotle LoumisCo-Founder
Mike TysonMike TysonCo-Founder
Ty BcTy BcCo-Founder
Old Pal
Old Pal
Series A$8M422018California, US
Board Member· Board

Leadership at Old Pal

Jason OsniJason OsniCo-Founder
Rusty WilenkinRusty WilenkinCo-Founder

Similar to Old Pal

Pilgrim SoulPilgrim SoulLos Angeles, CA, USCannabis, Productsest. 2019Pilgrim SoulLos Angeles, CA, US · est. 2019

Pilgrim Soul: A mission-driven cannabis brand enhancing human creativity for a competitive edge.

Seed · $2M5
Perfect BlendsPerfect BlendsLos Angeles, CA, USCannabis, Infused Productsest. 2019Perfect BlendsLos Angeles, CA, US · est. 2019

Perfect Blends: A cannabis brand offering 100% cannabis-infused products with extended shelf life.

Seed · $1M6
C3 IndustriesC3 IndustriesAnn Arbor, MI, USCannabis, Productsest. 2018C3 IndustriesAnn Arbor, MI, US · est. 2018

Premier, vertically-integrated cannabis producer with a national presence and high-quality products.

Series B · $50M750
Pioneer InterestsPioneer InterestsDenver, CO, USCannabis, Distributionest. 2018Pioneer InterestsDenver, CO, US · est. 2018

Pioneer Interests: A fully integrated cannabis company specializing in cultivation, distribution, and branding.

Series A · $15.9M20

Adam Wilks's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuLee Sirg-OoLee Sirg-OoCEO · DunamuIn-hyuk ChoiIn-hyuk ChoiCEO · Naver FinancialWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Adam Wilks

Steve OldhamSteve OldhamCEO · CapturaSai Kit NgSai Kit NgCEO · Captii VenturesMichael GeranenMichael GeranenCo-Founder & CEO · Captura Biopharma